Overview of Sinutab II

Sinutab II is a multi-symptom cold and sinus relief medicine offered as an Over-The-Counter (OTC) oral tablet. It is generally recognized as a combination product designed to simplify the symptomatic treatment of common respiratory illnesses.

Property	Description
Active Ingredients	Paracetamol (Acetaminophen) and Pseudoephedrine HCl
Form	Oral tablet or caplet
Pharmacological Class	Analgesic/Antipyretic + Oral Decongestant
Common Use	Symptomatic relief of pain, fever, and nasal/sinus congestion
Origin	Synthetic chemical compounds

Key Features and Pharmacological Purpose

Sinutab II utilizes a dual-action approach by combining two core ingredients: a pain reliever and a decongestant. This specific pairing is clinically recognized for providing additive relief, targeting both general systemic discomfort and localized congestion.

The formulation relies on Paracetamol to address the discomfort of fever and pain, acting as a non-opioid analgesic and antipyretic. The second key component is Pseudoephedrine hydrochloride, which is the decongestant. It is structurally classified as a sympathomimetic amine, which is the class of compounds used to temporarily relieve a "stuffy nose" associated with colds or allergies.

Differentiation from Related Products

This specific two-ingredient formulation of Paracetamol and Pseudoephedrine is commonly used to distinguish it from the multi-ingredient Sinutab versions that also include an antihistamine (like chlorpheniramine). The exclusion of the antihistamine is a key differentiating factor, making the two-ingredient Sinutab II a more focused, non-drowsy formulation primarily intended for patients whose primary symptoms are pain and congestion.

Regulatory References

Acetaminophen: MedlinePlus Drug Information

What side effects are possible with Sinutab II?

Adverse Effects Profile

Adverse reactions to this product, a combination of an analgesic, a decongestant, and an antihistamine, primarily affect the nervous system, gastrointestinal tract, and skin.

Commonly Observed Reactions include general systemic effects such as drowsiness, dizziness, and mild headache. Gastrointestinal disturbances like nausea, mild diarrhea, upset stomach, and dry mouth/nose/throat are also frequently reported. Nervous system effects often include a feeling of nervousness, restlessness, or sleep problems (insomnia). The elderly population may be more susceptible to side effects such as confusion, dizziness, and urinary difficulty.

Clinically Significant and Serious Adverse Reactions

Serious Adverse Reactions that require immediate cessation of use and medical attention are rare but include severe Hepatotoxicity (liver damage/failure) linked to the acetaminophen component, particularly in cases of overdose. The product is also associated with rare but potentially fatal Severe Cutaneous Adverse Reactions (SCARs), such as Stevens Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Cardiovascular effects, including dangerously high blood pressure (hypertensive crisis), cardiac dysrhythmias, and severe allergic reactions (anaphylaxis), are other serious risks documented for the component active ingredients. Severe CNS effects like seizures, hallucinations, and confusion have also been reported.

Safety Restrictions and Limitations

This medication is strictly contraindicated for use with or within 14 days of taking Monoamine Oxidase Inhibitors (MAOIs) due to the risk of severe drug interactions, including hypertensive crisis. Due to the risk of heightened central nervous system depression and increased risk of liver damage (Acetaminophen component), concomitant use with alcohol should be avoided. Caution is necessary for patients with pre-existing conditions such as glaucoma, uncontrolled high blood pressure, heart disease, severe liver or kidney dysfunction, overactive thyroid, or difficulty urinating (e.g., due to enlarged prostate). The product is not recommended for continuous use exceeding seven days.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official regulatory documents address the overdose profile of this combination product based on the known toxicity of its two active components. Immediate medical attention is required following any suspected overdose.

Overdose may present with initial gastrointestinal symptoms, including nausea, vomiting, pallor, and abdominal pain, primarily related to the Paracetamol component. However, government guidance mandates seeking urgent medical assistance even if the individual feels well, due to the delayed onset of potentially fatal hepatotoxicity (liver damage) which can progress without visible early symptoms.

Component	Potential Severe Outcomes (as documented)
Paracetamol	Hepatic failure, fatal hepatic necrosis, renal failure
Pseudoephedrine	Convulsions, hypertensive crisis, ventricular arrhythmias

The Pseudoephedrine component is associated with acute effects on the central nervous and cardiovascular systems, including restlessness, tremor, tachycardia, and a risk of hypertensive crisis. Life-threatening complications documented in official labeling include cerebral hemorrhage and malignant arrhythmias.

Specific regulatory procedures for overdose management involve the administration of acetylcysteine as a countermeasure for Paracetamol toxicity and general symptomatic and supportive treatment for both agents. Patients with pre-existing hepatic impairment are noted to have an increased risk of severe outcomes.

Therapeutic Uses of Sinutab II

The medication is generally used for symptomatic assistance in situations involving certain distressing symptoms.

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, and is used for conditions such as cold, flu, and allergic manifestations.

Easing Symptomatic Discomfort

This medication is commonly used when short-term symptomatic assistance is needed in managing symptom clusters that interfere with daily comfort. It is relevant in contexts marked by increased discomfort or tension, providing supportive relief for symptoms related to physical discomfort and heightened physiological activity. This support helps ease the overall symptom burden.

The medicine is applied in addressing symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity.

“It contributes to improved day-to-day comfort during periods of heightened symptoms.”

It is generally used across conditions associated with acute or disruptive episodes, and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Supports in situations involving physiological strain

This supportive action may assist with managing symptoms that create noticeable physiological strain and with maintaining functional stability during symptomatic phases.

Regulatory References

South African Health Products Regulatory Authority (SAHPRA) on Sinutab

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile for Sinutab II

The eligibility for Sinutab II, a combination of Paracetamol (Acetaminophen) and Pseudoephedrine HCl, is strictly defined by regulatory bodies through specific exclusions and limitations.

Eligibility Scope	Official Regulatory Status
Populations for whom use is allowed	Adults and adolescents typically aged 12 years and older (age threshold may vary by license).
Populations for whom use is contraindicated	Patients with severe hypertension, severe coronary artery disease, severe kidney failure, severe hepatic impairment, hyperthyroidism, phaeochromocytoma, or closed-angle glaucoma.
	Individuals with known hypersensitivity to the active ingredients or who are currently taking or have taken MAO Inhibitors within the last 14 days.
Age-related Eligibility Rules	The medicine is contraindicated in children under 12 years of age. Use in older adults requires caution due to increased susceptibility to effects from the Pseudoephedrine component.
Pregnancy and Lactation	Use is generally not recommended during pregnancy or lactation (breastfeeding), as the safety has not been fully established and components may pass into breast milk.
Condition-specific Restrictions	Use with caution in patients with non-severe hepatic impairment, moderate renal impairment, diabetes mellitus, or conditions that cause difficulty in urination.

Official regulatory documents define eligibility through absolute prohibitions and conditional restrictions linked to severe pre-existing health conditions or specific developmental stages. This structure precisely dictates the permitted patient population and those who are formally excluded.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes officially documented interaction patterns for the active ingredients, Paracetamol (Acetaminophen) and Pseudoephedrine HCl, as detailed in government regulatory documents.

Formal Restrictions and Contraindications

Co-administration with certain agents is formally restricted due to the risk of severe pharmacodynamic interactions:

Monoamine Oxidase Inhibitors (MAOIs): Use with Pseudoephedrine is contraindicated. Pseudoephedrine must not be used concurrently with MAOIs or within 14 days of discontinuing MAOI therapy.
Other Sympathomimetic Amines: Co-administration with other decongestants, appetite suppressants, or similar agents is generally contraindicated due to the risk of additive cardiovascular effects.

Documented Pharmacokinetic and Efficacy Alterations

Regulatory agencies document interactions that alter drug concentrations or efficacy:

Hepatic Enzyme Inducers: Co-administration with agents such as phenytoin, carbamazepine, and phenobarbital is associated with an increased risk of Paracetamol hepatotoxicity.
Oral Anticoagulants: Prolonged daily use of Paracetamol is documented to potentiate the effects of Warfarin, increasing the risk of bleeding.
Antihypertensives: Pseudoephedrine may reduce the antihypertensive efficacy of medications like beta-blockers and methyldopa.
Clearance Modifiers: Probenecid is documented to reduce Paracetamol clearance, while urinary alkalinizing agents may reduce Pseudoephedrine excretion, leading to increased plasma concentrations.

Substance and Population Considerations

Chronic, heavy alcohol use is officially noted to increase the risk of Paracetamol-induced liver injury. Furthermore, interaction risks related to Paracetamol are acknowledged as more clinically significant in patients with hepatic impairment when combined with alcohol or enzyme inducers.

Mechanism of Action

Central Modulation of Thermoregulation and Pain Signaling

This domain describes the action of Paracetamol, which functions as an inhibitor of cyclooxygenase ( COX) enzyme activity predominantly within the central nervous system (CNS). By reducing the synthesis of Prostaglandin E2 ( PGE2) in the hypothalamus, the mechanism acts to reset the body's elevated thermal set-point, initiating the physiological cascade resulting in heat dissipation. The drug also engages pathways that modulate the central transmission of nociceptive signals.

Autonomic Regulation of Mucosal Vascular Tone

This domain focuses on Pseudoephedrine HCl, which is a sympathomimetic amine that directly and indirectly activates boldsymbolalpha1 -Adrenergic Receptors (boldsymbolalpha1 AR) on the smooth muscle of arterioles. This specific boldsymbolalpha1 AR agonism leads to vasoconstriction in the upper respiratory tract's mucosal lining. The resulting physiological consequence is a reduction in local blood volume and tissue fluid leakage, leading to detumescence of mucosal tissue.

Parallel and Independent Mechanistic Action

The combination utilizes a parallel mechanism, where Paracetamol addresses central regulatory processes and Pseudoephedrine addresses peripheral vascular tone regulation. These two independent mechanistic pathways produce an additive physiological outcome, which achieves modulation across distinct core systems—CNS signaling and autonomic vascular control.

Dosage and Administration Information

Official Administration Guidelines for Sinutab II

Sinutab II is a combination product for oral use only. The official usage is defined by labeled dose quantities and time intervals to prevent accidental over-consumption of the active ingredients, Paracetamol and Pseudoephedrine HCl. The medicine is intended for short-term use only and should be discontinued if symptoms exceed 3 to 5 days.

Instruction Category	Official Guideline
Route of Administration	Oral use, taken with a glass of water.
Adult Dosing	Two tablets per dose (1000 mg Paracetamol / 60 mg Pseudoephedrine HCl).
Frequency and Schedule	Repeat dose every 4 to 6 hours, ensuring a minimum interval of 4 hours between doses.
Maximum Daily Limit	Do not exceed 8 tablets (4000 mg Paracetamol / 240 mg Pseudoephedrine HCl) in any 24-hour period.
Adolescent Dosing	12 to 15 years: One tablet (500 mg Paracetamol / 30 mg Pseudoephedrine HCl) every 4 to 6 hours, up to 4 doses daily.

Procedural Structure

The usage protocol is based on as-needed (PRN) administration, with the quantity of tablets varying by age group. The official instructions strictly mandate that the user must not take more than 4 doses in a 24-hour period. If a dose is missed, the user is instructed to take the next scheduled dose when needed, provided the 4-hour minimum interval has elapsed, and not to take a double dose to compensate. Administration should cease if the prescribed short-term use limit is reached.

Recent Clinical Evidence

Research evidence / Overview of Studies for Sinutab II (Paracetamol/Pseudoephedrine)

Evidence for Symptom Management in Acute Colds and URTIs

The foundation of clinical research for this combination includes Randomized Controlled Trials (RCTs). Research has explored the use of this two-ingredient combination in individuals with symptoms of the common cold and other acute upper respiratory tract infections (URTIs), which are conditions characterized by episodic or disruptive symptom patterns. In these trials, studies typically compared the combination product against an inactive control (placebo) and often against the individual ingredients taken alone.

These studies focused on outcomes related to physical discomfort and functional imbalance, examining measures like nasal obstruction using objective methods, and patient-reported outcomes for symptoms like headache, feverishness, and nasal congestion. Studies report how symptoms evolved in the observed populations over defined, short time intervals.

Study Duration and Follow-up Assessments

The existing body of clinical evidence for this combination has primarily focused on short-term symptom outcomes. Most of the pivotal RCTs monitor changes in symptoms over the initial single-dose window or during multi-dose use lasting up to three days. Because the research focuses heavily on acute changes, there is limited information available for the outcomes of patients who continue use beyond the immediate, acute phase of the illness. Long-term effects are not fully established.

Evidence in Specific Patient Populations

The published research on the Paracetamol/Pseudoephedrine combination was primarily conducted in generally healthy adults between the ages of 18 and 65. Due to the selective inclusion criteria of the clinical trials, the data for certain groups remain insufficient. For instance, there is limited information from controlled studies examining the research base for this combination in older adults or in individuals taking medications for long-term chronic diseases. Consequently, results apply primarily to the healthy adult populations studied.

Research Gaps and Areas of Uncertainty

While research provides context on how symptoms change over time, a key limitation is the focus on short, episodic symptom patterns; comparative evidence regarding the combination's use over extended periods is lacking. Furthermore, existing studies provide limited insight into the generalizability of the findings, as sample sizes were often modest. Research does not determine whether an individual will respond similarly to the group patterns observed in the trials.

Key Studies & References

NICE guideline: Common cold (non-specific upper respiratory tract infection)

Frequently Asked Questions (FAQ)

Common questions about Sinutab II (FAQ)

Q: How quickly do people typically start noticing the effects of Sinutab II?

Regulatory information indicates that the decongestant ingredient, pseudoephedrine, is documented to begin acting in approximately 30 minutes. This timeframe indicates when the intended effect on congestion may begin.

Q: How long does the intended effect of Sinutab II last?

The duration of the intended effect is generally documented to be between 4 and 6 hours for the immediate-release formulation. This timeframe is consistent with the general time interval described in official guidelines.

Q: Is Sinutab II generally safe for people who are older than 65?

Official documentation indicates that use in older adults requires caution due to a potential increased susceptibility to certain side effects of the active ingredients. Official information suggests that consultation is advised before use, particularly for individuals with pre-existing conditions.

Q: What happens if someone accidentally uses Sinutab II more often than directed?

Exceeding the recommended dosage may cause severe adverse effects, including serious liver damage from the paracetamol component. In cases of accidental overuse, official product information states that medical assistance should be sought immediately.

Q: Why is Sinutab II sometimes mentioned in discussions about headache relief?

The product contains paracetamol, which is classified as an analgesic (pain reliever). This ingredient is specifically included to relieve the aches and pain, which encompasses headaches, associated with cold and flu symptoms.

Q: Can taking Sinutab II cause a dry mouth?

Yes, dry mouth, along with dry nose and throat, is documented in the adverse effects profile as a commonly reported reaction to the active ingredients.

Q: Can Sinutab II affect how other pain relievers work?

Regulatory documents describe interactions for the paracetamol component. For example, prolonged use alongside other non-steroidal anti-inflammatory drugs (NSAIDs) is documented to potentially increase the risk of adverse renal effects.

Q: Is there a version of Sinutab II that is intended for nighttime use?

The specific two-ingredient formulation of Sinutab II is described as a non-drowsy product. Other multi-ingredient products under the Sinutab name, which may include components like an antihistamine, are sometimes available for nighttime use.

Q: Are there any non-drug ingredients in Sinutab II that users should be aware of?

Official documentation includes a list of all non-active ingredients (excipients) used in the tablet formulation. This list is typically detailed in Section 6 of the Patient Information Leaflet.

Q: Is Sinutab II available over-the-counter or does it require a prescription?

This product is classified and marketed as an Over-The-Counter (OTC) medication. It is available for purchase without a doctor's prescription.

Q: Is it possible to develop a tolerance to Sinutab II?

Regulatory documentation warns that continuous use may lead to a diminished effect, potentially resulting in the user exceeding the recommended dose to achieve the desired relief. The product is intended only for short-term use.

Q: Is Sinutab II described as non-habit forming?

While the product is not classified as habit-forming in the traditional sense, the active ingredient pseudoephedrine has been flagged in regulatory documents as having a potential for abuse. Official guidance suggests that use should not extend beyond the recommended duration.

Q: Can Sinutab II be used if someone has asthma?

Regulatory guidance notes that patients with a persistent respiratory condition, such as asthma, are advised to consult a healthcare professional before using the product.

Q: Is Sinutab II known to affect heart rate?

The decongestant ingredient is documented to potentially cause a small increase in heart rate. More seriously, it may rarely cause irregular or very fast heart rate (cardiac dysrhythmias) as a serious adverse reaction.

Q: Is Sinutab II intended to treat the root cause of symptoms?

Official descriptions state that the product is intended purely for the symptomatic relief of pain, fever, and congestion. It does not treat the underlying cause of the cold, flu, or related illness.

Q: Why does the packaging for Sinutab II warn about driving or operating machinery?

Documented effects such as dizziness or drowsiness are the basis for this caution on the packaging. These effects involve the central nervous system and should be noted by the user.

Q: Does Sinutab II have a known effect on blood sugar levels?

The pseudoephedrine component may potentially interfere with blood sugar control. Official guidance notes that patients with diabetes mellitus are advised to use the product with caution.

Q: Why do some people say they use Sinutab II for their seasonal allergies?

The product contains pseudoephedrine, a decongestant that is officially indicated for the temporary relief of nasal congestion. This includes congestion associated with the common cold, hay fever, or other upper respiratory allergies.

Q: Does the efficacy of Sinutab II change with age?

The research evidence for the combination product focuses primarily on healthy adults. Documentation notes that there is limited data available regarding the generalizability of findings, including efficacy, in older adult populations.

Q: Are there different strengths of Sinutab II available?

The base strength of the tablets is defined by the fixed amount of active ingredients per tablet (e.g., Paracetamol and Pseudoephedrine HCl). The total dose strength administered is adjusted by the number of tablets taken, as detailed in the official guidelines for adults and adolescents.

Q: Is Sinutab II described as having an antihistamine component?

This specific two-ingredient formulation is described as a non-drowsy product that does not contain an antihistamine component, which is a key difference from other multi-ingredient versions.

Q: Can Sinutab II be used to help with ear congestion?

The decongestant ingredient, pseudoephedrine, is officially indicated for the temporary relief of congestion. This can include nasal, sinus, and sometimes ear congestion associated with colds or allergies.

Q: Is it normal for some people to experience mild stomach upset with Sinutab II?

Gastrointestinal disturbances are among the commonly reported adverse reactions to the product. These can include mild nausea, diarrhea, or a general feeling of stomach upset.

How should Sinutab II be stored and disposed of?

Sinutab II tablets must be stored at room temperature, typically between 20 C to 25 C (68 F to 77 F), and should not be stored above 25 C. The container must be kept tightly closed in its original packaging and protected from light and moisture; avoid storage in high-humidity areas like a bathroom. Liquid forms of the medicine must not be frozen.

Child Safety and Disposal

All medication must be kept out of the sight and reach of children and pets, ideally in a secure, locked location. Disposal of expired or unused medication must follow local regulations or utilize drug take-back programs. If take-back options are unavailable, the medicine can be mixed with an undesirable substance (such as dirt) and sealed in a bag for disposal in the household trash; do not flush down the toilet.

Sinutab II